Transgene脱落120作业以节省现金，并得到其管道运动

StephenW

Transgene is shedding 120 jobs to save cash and get its pipeline moving
French biotech Transgene is planning to slash its payroll and redouble its focus on clinical development, moving on from a costly snub at the hands of Novartis ($NVS).

The company will let go of about 120 employees as it steps away from vertical integration, cutting its losses in development and manufacturing with the goal of leaning on contractors to fill the void. With the resulting savings, Transgene plans to focus on R&D, investing in its pipeline of mid-stage treatments and laying out funds for translational research, the company said.

Transgene is also using the opportunity to rethink its approach to developing drugs, according to management, looking more to collaborations with academia and biopharma partners and vowing to consider deals at earlier stages of the process.

The change, which sent Transgene's shares down about 14%, comes about a year after ex-partner Novartis decided against opting in on TG4010, a Phase II vaccine targeting lung cancer. The Swiss drugmaker's decision nixed an agreement worth as much as $800 million, deflating Transgene's market value in the process. The biotech has since promised to go it alone on a Phase III trial for TG4010 but is yet to begin enrollment.

Transgene has stressed that it will do everything it can to find new jobs for the employees affected by its latest cuts, working with top shareholder Institut Mérieux to place them. The company is "committed to by all means minimizing as much as possible the social impact of the restructuring plan," management said in a statement, and the goal "is to leave no one without a solution."

Meanwhile, Transgene and partner SillaJen are blueprinting a Phase III trial for Pexa-Vec, a vaccine for liver cancer that missed its main goal in Phase IIb. The partners got the FDA's sign-off on their proposed study design in April and plan to enroll about 600 patients later this year. Transgene is also at work on earlier stage therapies for HPV-induced cancers, solid tumors, hepatitis B and tuberculosis.

StephenW

转基因脱落120作业以节省现金，并得到其管道运动
法国转基因生物技术正计划削减其工资和加倍注重临床开发，从昂贵的冷落在移动诺华（NVS $）的手中。

该公司将放手约120名员工，因为它几步之遥的垂直整合，减少其在开发和制造损失与承包商靠在填补空缺的目标。与所得的积蓄，转基因计划将重点放在研发，投资于中期的治疗方法其管道和铺设的资金转化研究，该公司表示。

转基因也利用这个机会重新考虑其方法来开发药物，依法管理，寻找更多的合作与学术界和生物制药的合作伙伴，并声称要考虑在前面的过程阶段的交易。

这种变化，其中转基因派的股价下跌了约14％，之前约一年后的前合作伙伴诺华公司决定对在TG4010，二期疫苗靶向肺癌选择加入。瑞士制药商的决定，否决了一项协议，价值高达800多万元，在这个过程中放气转基因的市场价值。生物技术一直以来承诺单干的III期试验为TG4010，但尚未开始招生。

转基因还强调，将尽一切可能找到受到其最新的削减员工新的就业机会，与大股东梅里厄研究所合作，将它们放置。该公司管理层在一份声明中说的是“要通过最小化，尽可能的重组计划的社会影响一切手段，承诺”和目标“是不会让任何人没有一个解决方案。”

同时，转基因和合作伙伴都SillaJen计划过程III期试验Pexa-VEC，疫苗肝癌错过在IIb阶段的主要目标。该合作伙伴得到了FDA的注销对他们提出的研究设计在四月，并计划在今年晚些时候招收约600名患者。转基因也处于早先阶段疗法HPV诱发的癌症，实体瘤，乙型肝炎和肺结核的工作。